Table 2.
Sample processing and culture conditions.
| Study | Dissociation (Time, Min) | Strainer | Fraction | Matrix | Base Medium | Growth Factors, Other |
|---|---|---|---|---|---|---|
| Burgues 2007 [29] | M | no | NA | no | DMEM | FBS, L-glut, neaa |
| Fierabracci 2007 [30] | E (NA) | no | fragments | no | DMEM/F12 | INS, Tf, PGT, putrescine, sodium selenite, β-met, bFGF, EGF |
| Bentivegna 2010 [31] | M&E (120–180) | 40 | FT | no | Adv DMEM/F-12 | EGF, bFGF with or without FCS |
| Hofner 2013 [25] | E (60–120) | 40 | FT | no | DMEM/F-12 | Refer to the article |
| Okuyama 2013 [22] | M&E (120) | NA | retained on strainer | Cellmatrix | DMEM/F12 | (a) (Glutamax, BSA, β-met, bFGF), HRG, activin A, long-IGF |
| Yoshida 2015a [23] | M&E (NA) | 100, 40 | retained on 100 or 40 | no | DMEM/F12 | (a) (Glutamax, BSA) |
| Yoshida 2015b [24] | M&E (NA) | 100, 40 | retained on 100 or 40 | Collagen I | DMEM/F12 | (a) (Glutamax, BSA) |
| Gabig 2016 [26] | M&E (120) | NA | retained on strainer | Matrigel | DMEM/F12 | (a) (Glutamax, BSA, β-met, bFGF), HRG |
| Gheibi 2017 [32] | M&E (25) | 180, 40 | retained on 40 | Matrigel | RPMI | B27, EGF, bFGF or 30%FBS (PDX) |
| Pauli 2017 [33] | M&E (NA) | no | pellet | Matrigel | Adv DMEM/F-12 | Glutamax, B27, Nac, NAM, EGF, FGF10, bFGF, A83-01, R-spondin, Noggin, PGE2, SB202190, ROCKi |
| Ooki 2018 [34] | M&E | NA | High-CD24, Low-CD24 | no | DMEM/F-12 | B27, EGF, bFGF |
| Lee 2018 [15] | M&E (15, 4) | 100 | FT | Matrigel | hepatocyte medium | Glutamax, EGF, ROCKi, FBS |
| Yoshida 2018 [35] | M&E (NA) | no | NA | no | DMEM/F-12 | Glutamax, BSA, β-met |
| Neal 2018 [27] | M | no | all | Collagen I | Adv DMEM/F-12 | Glutamax, HEPES, B27, Nac, NAM, A83-01, R-spondin, Noggin, EGF, Gastrin, SB202190, Wnt3a |
| Kita 2019 [36] | M&E (NA) | no | NA | Matrigel | As in Yoshida2018 | As in Yoshida2018 |
| Mullenders 2019 [17] | M&E (60) | 70 | FT | BME | Adv DMEM/F-12 | B27, Nac, NAM, A83-01, FGF2/7/10, ROCKi |
| Kim 2020 [37] | M&E (60) | 100 | FT | Matrigel | Adv DMEM/F-12 | Glutamax, HEPES, B27, Nac, NAM, A83-01, EGF, ROCKi |
| Whyard 2020 [19] | M&E (120) | 40 | retained on 40 | BME | Adv DMEM/F-12 | B27, Nac, NAM, A83-01, FGF2/7/10, HER3, ROCKi |
| Namekawa 2020 [38] | M&E (60) | 100 | FT | no | DMEM/F-12 | (a) (Glutamax, BSA, bFGF), ROCKi |
| Yoon 2020 [28] | M&E (60) | 100 | FT | Matrigel | Adv DMEM | Glutamax, HEPES, B27, Nac, NAM, A83-01, EGF, ROCKi |
| Amaral 2020 [39] | M&E (40–60) | 100 | FT | Matrigel | RPMI-1640 | FBS, L-glut, neaa |
| Murakami 2021 [40] | E (75) | 100, 40 | retained on 100 or 40 | Matrigel | DMEM/F-12 | Glutamax, StemPro, BSA, β-met |
| Yu 2021 [41] | M&E (50) | 70 | FT | Matrigel | Adv DMEM/F-12 | Glutamax, HEPES, B27, Nac, NAM, A83-01, R-spondin, Noggin, EGF, FGF2/10, SB202190 |
| Cai 2021 [16] | M&E (65) | 40 | FT | Matrigel | Adv DMEM/F-12 | B27, NAC, A83-01, R-spondin, Noggin, EGF, ROCKi |
M: mechanical dissociation; E: enzymatic dissociation; FT: flow-through; FBS: fetal bovine serum; neaa: nonessential amino acids; EGF: epidermal growth factor; INS: insulin; Tf: transferrin; PGT: progesterone; β-met: 2-mercaptoethanol; bFGF: basic fibroblast growth factor; HGF: hepatocyte growth factor; Nac: N-acetylcysteine; NAM: nicotinamide; ROCKi: rho kinase inhibitor (Y-27632); HRG: heregulinB1.(a) StremPro hESC SFM components, unclear from the reports if additional supplements were added.